ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1573

Inpatient Prevalence and Comorbidity of Takayasu’s Arteritis: Nationwide Inpatient Sample 2016-2020
Abstract Number: 1692

Insights on the Use of JAK-inhibitors in Patients with Psoriatic Arthritis in an International Collaboration of Registers (the “JAK-pot” Study)
Abstract Number: 0565

Insulin Resistance and the Complement System Are Linked in Patients with Systemic Lupus Erythematosus
Abstract Number: 2095

Integrated Analysis of Gene Expression and Methylation Identifies Biomarkers Associated with Mode of Action of Upadacitinib Treatment in Rheumatoid Arthritis
Abstract Number: 1773

Integrated Analysis of Rheumatoid Arthritis (RA) Fibroblast-like Synoviocytes (FLS) Transcriptome and Chromatin Accessibility Identifies Mechanisms Associated with Location-specific Disease Severity
Abstract Number: 0116

Integrated Metabolomic and Proteomic Analyses Stratified Patients with Antiphospholipid Syndrome According to Their Atherothrombotic Risk
Abstract Number: 1325

Integrated Safety Analysis of Filgotinib in Patients with Moderate to Severe Active Rheumatoid Arthritis with a Maximum Exposure of 8.3 Years
Abstract Number: 2431

Integrated Single Cell Multi-omics Analysis in At-Risk for Future Rheumatoid Arthritis (RA) and Early RA Reveals Shared Transcription Factor Profiles in Multiple Cell Lineages
Abstract Number: 2068

Integration of Basic Science into Virtual Patient Cases to Enhance Clinical Reasoning Skills
Abstract Number: 1783

Integrative Functional Genomics Points to Natural Killer Cells as Key Drivers in the Pathogenesis of Ankylosing Spondylitis
Abstract Number: 1875

Inter and Intra-observer Reliability of Assessment for Nailfold Capillary Abnormalities in Rheumatic Patients with Raynaud’s Phenomenon
Abstract Number: 0041

Interactions Between Synovial Fibroblasts and Macrophages: Implications for Tissue Remodeling in Chronic Inflammatory Diseases and Macrophage Differentiation in Response to the Immune Microenvironment
Abstract Number: 2297

Interferon-α as a Biomarker to Predict Flares in Lupus Nephritis
Abstract Number: 2078

Interim Evaluation of a 6 Year Remote Online Adaptive Learning Platform Module for Rheumatology Fellows: Applied Rheumatology on the Go
Abstract Number: 2447

Interleukin-6 Activates Glial Cells and Induces Cognitive Dysfunction in Murine Neuropsychiatric Lupus

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].